Why would INSM cut the NTM study off at 90 patients enrolled . . . and then indicate that they are starting the SWAP paperwork? This was always the first and best hope for INSM and I think that this will be demonstrated pretty soon.
KN Olivier of NIH and Clinician of record for the NTM clinical trial appears to have caught fire in 2013. Sixteen papers on various inhalational therapies and genetic mutations associated with pulmonary dysfunction.